A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma

Julian Garcia-Feijoo, Juan Roberto Sampaolesi, Julian Garcia-Feijoo, Juan Roberto Sampaolesi

Abstract

Background: Glaucoma can be associated with an increase in the occurrence of ocular surface disease (OSD) symptoms. The objective of this study was to examine the prevalence of ocular surface complaints in patients with glaucoma who used topical intraocular pressure (IOP)-lowering therapies.

Methods: In this multicenter, international, noninterventional study, adults with glaucoma or ocular hypertension who were using 1 or more topical IOP-lowering medications completed the Ocular Surface Disease Index (OSDI) questionnaire during a regularly scheduled clinic visit. OSDI scores (ranging from 0 to 100) were calculated for each patient. An OSDI score ≥13 indicated a clinically relevant presence of OSD.

Results: Of the 448 patients who were evaluated, 53.3% were women, 61.6% had a diagnosis of primary open-angle glaucoma, and the mean age was 63 years. The overall OSD prevalence rate in the evaluable population was 59.2%, with 25.7%, 13.2%, and 20.3% of the patients reporting mild, moderate, or severe OSD symptoms, respectively. Patients with glaucoma diagnoses of less than 6 years had a significantly lower mean OSDI score relative to patients with glaucoma diagnoses of 6 years or more (18 [mild OSD] versus 23 [moderate OSD], respectively; P = 0.03). As the number of IOP-lowering treatments increased from one or two medications to three or four medications, the mean OSDI score increased from mild to moderate, though the difference in scores was not statistically significant (P = 0.15).

Conclusions: OSD was highly prevalent in this population of glaucoma patients who were using IOP-lowering medications. Longer duration since diagnosis was significantly correlated with worsening of OSD symptoms. Increases in the number of medications applied also showed a clinically relevant increase in OSD symptom severity.

Keywords: OSDI; correlation; number of medications; time since diagnosis.

Figures

Figure 1
Figure 1
Number and percentage of glaucoma patients with Ocular Surface Disease Index scores indicating normal ocular surface or the presence of mild, moderate, or severe dry eye/ocular surface disease complaints (evaluable patients). Abbreviation: OSDI, Ocular Surface Disease Index.

References

    1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007;2007;5(2):75–92.
    1. Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391–398.
    1. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146(3):350–356.
    1. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405–412.
    1. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;135(1):1–9.
    1. Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol. 2010;21(4):310–316.
    1. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S102–S106.
    1. Schein OD, Hochberg MC, Muñoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999;159(12):1359–1363.
    1. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334.
    1. Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S88–S101.
    1. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355.
    1. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621.
    1. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19(4):572–579.
    1. Rossi GCM. How to diagnose the ocular surface disease in treated glaucoma patients. Eur Ophthalmic Rev. 2011;5(1):38–42.
    1. Schiffman RM, Christianson MD, Jacobsen G. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615–621.
    1. Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1593–1601.
    1. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002;53(3):263–280.
    1. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009;28(3):93–103.
    1. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205–215.
    1. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18(2):134–139.
    1. Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011;28(4):267–282.
    1. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863–868.
    1. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23(8):762–770.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir